JP6142069B1 - 抗ミオスタチン抗体、変異Fc領域を含むポリペプチド、および使用方法 - Google Patents

抗ミオスタチン抗体、変異Fc領域を含むポリペプチド、および使用方法 Download PDF

Info

Publication number
JP6142069B1
JP6142069B1 JP2016244254A JP2016244254A JP6142069B1 JP 6142069 B1 JP6142069 B1 JP 6142069B1 JP 2016244254 A JP2016244254 A JP 2016244254A JP 2016244254 A JP2016244254 A JP 2016244254A JP 6142069 B1 JP6142069 B1 JP 6142069B1
Authority
JP
Japan
Prior art keywords
antibody
seq
amino acid
myostatin
hvr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016244254A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017112997A (ja
Inventor
太一 倉持
太一 倉持
智之 井川
智之 井川
仁 堅田
仁 堅田
裕次 堀
裕次 堀
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Application granted granted Critical
Publication of JP6142069B1 publication Critical patent/JP6142069B1/ja
Publication of JP2017112997A publication Critical patent/JP2017112997A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06Anabolic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • C07K2317/524CH2 domain
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • C07K2317/526CH3 domain
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • C07K2317/53Hinge
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567Framework region [FR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71Decreased effector function due to an Fc-modification
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2016244254A 2015-12-18 2016-12-16 抗ミオスタチン抗体、変異Fc領域を含むポリペプチド、および使用方法 Active JP6142069B1 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015247070 2015-12-18
JP2015247070 2015-12-18

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017092151A Division JP7053164B2 (ja) 2015-12-18 2017-05-08 抗ミオスタチン抗体、変異Fc領域を含むポリペプチド、および使用方法

Publications (2)

Publication Number Publication Date
JP6142069B1 true JP6142069B1 (ja) 2017-06-07
JP2017112997A JP2017112997A (ja) 2017-06-29

Family

ID=59011957

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2016244254A Active JP6142069B1 (ja) 2015-12-18 2016-12-16 抗ミオスタチン抗体、変異Fc領域を含むポリペプチド、および使用方法
JP2017092151A Active JP7053164B2 (ja) 2015-12-18 2017-05-08 抗ミオスタチン抗体、変異Fc領域を含むポリペプチド、および使用方法
JP2022058710A Pending JP2022097485A (ja) 2015-12-18 2022-03-31 抗ミオスタチン抗体、変異Fc領域を含むポリペプチド、および使用方法
JP2023201204A Pending JP2024023427A (ja) 2015-12-18 2023-11-29 抗ミオスタチン抗体、変異Fc領域を含むポリペプチド、および使用方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2017092151A Active JP7053164B2 (ja) 2015-12-18 2017-05-08 抗ミオスタチン抗体、変異Fc領域を含むポリペプチド、および使用方法
JP2022058710A Pending JP2022097485A (ja) 2015-12-18 2022-03-31 抗ミオスタチン抗体、変異Fc領域を含むポリペプチド、および使用方法
JP2023201204A Pending JP2024023427A (ja) 2015-12-18 2023-11-29 抗ミオスタチン抗体、変異Fc領域を含むポリペプチド、および使用方法

Country Status (16)

Country Link
EP (1) EP3390443A4 (ko)
JP (4) JP6142069B1 (ko)
KR (4) KR20240058997A (ko)
CN (2) CN115028721A (ko)
AR (1) AR107078A1 (ko)
AU (1) AU2016372934B2 (ko)
BR (1) BR112018011073A2 (ko)
CA (1) CA3002422C (ko)
EA (1) EA201891420A1 (ko)
HK (1) HK1254755A1 (ko)
MX (1) MX2018007145A (ko)
MY (1) MY189425A (ko)
PH (1) PH12018501280A1 (ko)
SG (2) SG11201610812WA (ko)
TW (3) TW202231662A (ko)
WO (1) WO2017104783A1 (ko)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017148069A (ja) * 2015-12-18 2017-08-31 中外製薬株式会社 抗ミオスタチン抗体、変異Fc領域を含むポリペプチド、および使用方法

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11046784B2 (en) 2006-03-31 2021-06-29 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
SI2202245T1 (sl) 2007-09-26 2016-10-28 Chugai Seiyaku Kabushiki Kaisha Postopek modificiranja izoelektrične točke protitelesa preko aminokislinske substitucije v CDR
CN107488228A (zh) 2008-04-11 2017-12-19 中外制药株式会社 与多个分子的抗原反复结合的抗原结合分子
RU2658504C9 (ru) 2010-11-30 2018-08-21 Чугаи Сейяку Кабусики Кайся Антигенсвязывающая молекула, способная многократно связываться с множеством антигенных молекул
CN107964042B (zh) 2012-05-30 2022-04-19 中外制药株式会社 靶组织特异性抗原结合分子
WO2014030750A1 (ja) 2012-08-24 2014-02-27 中外製薬株式会社 マウスFcγRII特異的Fc抗体
KR20210084688A (ko) 2012-08-24 2021-07-07 추가이 세이야쿠 가부시키가이샤 FcγRIIb 특이적 Fc영역 개변체
EP3783017A1 (en) 2013-04-02 2021-02-24 Chugai Seiyaku Kabushiki Kaisha Fc region variant
AU2014358191B2 (en) 2013-12-04 2020-12-24 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecules, the antigen-binding activity of which varies according to the concentration of compounds, and libraries of said molecules
EP3240804A4 (en) 2014-12-19 2019-01-09 Chugai Seiyaku Kabushiki Kaisha ANTI-MYOSTATIN ANTIBODIES, POLYPEPTIDES WITH DEVIANT FC REGIONS AND METHOD OF USE
EP3816179A3 (en) 2015-02-05 2021-08-04 Chugai Seiyaku Kabushiki Kaisha Fc region variant comprising a modified fcrn-binding domain
EP3394098A4 (en) 2015-12-25 2019-11-13 Chugai Seiyaku Kabushiki Kaisha ANTI-MYOSTATIN ANTIBODIES AND METHODS OF USE
EA201990017A1 (ru) * 2016-06-17 2019-07-31 Чугаи Сейяку Кабусики Кайся Антитела к миостатину и способы их применения
KR20230079499A (ko) 2016-08-05 2023-06-07 추가이 세이야쿠 가부시키가이샤 Il-8 관련 질환의 치료용 또는 예방용 조성물
WO2018160683A1 (en) 2017-02-28 2018-09-07 Seattle Genetics, Inc. Cysteine mutated antibodies for conjugation
KR102259473B1 (ko) 2018-08-10 2021-06-02 추가이 세이야쿠 가부시키가이샤 항cd137 항원 결합 분자 및 그의 사용
KR20210149779A (ko) * 2019-04-10 2021-12-09 추가이 세이야쿠 가부시키가이샤 Fc 영역 개변 항체의 정제 방법
EP4028417A4 (en) * 2019-09-13 2024-01-24 Admare Therapeutics Soc ANTIBODIES AGAINST ONCOLYTIC VIRUS ANTIGEN AND METHODS OF USE THEREOF
RU2750267C1 (ru) * 2020-02-07 2021-06-25 Общество с ограниченной ответственностью «НАУЧНО-ПРОИЗВОДСТВЕННОЕ ОБЪЕДИНЕНИЕ ИН-ВЕТ» Рекомбинантный ростовой дифференцировочный фактор роста 11 (GDF11), способ его получения, инъекционный препарат для повышения мышечной массы млекопитающих животных и птицы, а также способ использования препарата
TW202144395A (zh) 2020-02-12 2021-12-01 日商中外製藥股份有限公司 用於癌症之治療的抗cd137抗原結合分子
CN118055767A (zh) 2021-10-06 2024-05-17 豪夫迈·罗氏有限公司 新颖的组合施用
WO2023187022A1 (en) 2022-04-01 2023-10-05 F. Hoffmann-La Roche Ag New treatment for facioscapulohumeral muscular dystrophy (fshd)
TWI833641B (zh) 2022-05-02 2024-02-21 丹麥商諾佛 儂迪克股份有限公司 適於高濃度組成物及皮下投藥之新穎抗angptl3抗體
WO2024081932A1 (en) 2022-10-14 2024-04-18 Genentech, Inc. Methods for treating spinal muscular atrophy
CN116990528B (zh) * 2023-09-27 2024-02-06 成都华西海圻医药科技有限公司 一种基于Gyrolab平台快速测定抗CD40单抗的分析方法

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006519583A (ja) * 2002-10-22 2006-08-31 ワイエス Gdf−8に対する中和抗体およびそれらの使用
WO2009125825A1 (ja) * 2008-04-11 2009-10-15 中外製薬株式会社 複数分子の抗原に繰り返し結合する抗原結合分子
JP2011504096A (ja) * 2007-11-01 2011-02-03 ワイス・エルエルシー その使用としてのgdf8に対する抗体
JP2012512641A (ja) * 2008-12-19 2012-06-07 グラクソ グループ リミテッド ミオスタチン結合タンパク質
JP2013531486A (ja) * 2010-06-03 2013-08-08 グラクソ グループ リミテッド ミオスタチン6に対するヒト化抗原結合タンパク質
WO2016073853A1 (en) * 2014-11-06 2016-05-12 Scholar Rock, Inc. Anti-pro/latent-myostatin antibodies and uses thereof
WO2016098357A1 (en) * 2014-12-19 2016-06-23 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7320789B2 (en) * 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
SI1797127T1 (sl) * 2004-09-24 2017-09-29 Amgen Inc. Modificirane fc-molekule
US8008453B2 (en) * 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
PT2066695E (pt) * 2006-09-05 2013-05-23 Lilly Co Eli Anticorpos anti-miostatina
SG10201507722QA (en) * 2010-03-11 2015-10-29 Rinat Neuroscience Corp ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING
EP3348140B1 (en) * 2012-03-16 2020-12-30 Regeneron Pharmaceuticals, Inc. Histidine engineered light chain antibodies and genetically modified rodents for generating the same
TWI619729B (zh) * 2012-04-02 2018-04-01 再生元醫藥公司 抗-hla-b*27抗體及其用途
EA028244B1 (ru) * 2012-08-13 2017-10-31 Ридженерон Фармасьютикалз, Инк. АНТИТЕЛА К PCSK9 C pH-ЗАВИСИМЫМИ ХАРАКТЕРИСТИКАМИ СВЯЗЫВАНИЯ
KR20210084688A (ko) * 2012-08-24 2021-07-07 추가이 세이야쿠 가부시키가이샤 FcγRIIb 특이적 Fc영역 개변체
CA2911514A1 (en) * 2013-05-06 2014-11-13 Scholar Rock, Inc. Compositions and methods for growth factor modulation
CA2918300A1 (en) * 2013-08-14 2015-02-19 Novartis Ag Methods of treating sporadic inclusion body myositis
WO2016073879A2 (en) * 2014-11-06 2016-05-12 Scholar Rock, Inc. Transforming growth factor-related antibodies and uses thereof
TW202231662A (zh) 2015-12-18 2022-08-16 日商中外製藥股份有限公司 抗肌抑素抗體、含變異fc區之多肽及使用方法

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006519583A (ja) * 2002-10-22 2006-08-31 ワイエス Gdf−8に対する中和抗体およびそれらの使用
JP2011504096A (ja) * 2007-11-01 2011-02-03 ワイス・エルエルシー その使用としてのgdf8に対する抗体
WO2009125825A1 (ja) * 2008-04-11 2009-10-15 中外製薬株式会社 複数分子の抗原に繰り返し結合する抗原結合分子
JP2012512641A (ja) * 2008-12-19 2012-06-07 グラクソ グループ リミテッド ミオスタチン結合タンパク質
JP2013531486A (ja) * 2010-06-03 2013-08-08 グラクソ グループ リミテッド ミオスタチン6に対するヒト化抗原結合タンパク質
WO2016073853A1 (en) * 2014-11-06 2016-05-12 Scholar Rock, Inc. Anti-pro/latent-myostatin antibodies and uses thereof
WO2016098357A1 (en) * 2014-12-19 2016-06-23 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6017002993; 京府医大誌 vol.122,no.3, 2013, p.133-141 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017148069A (ja) * 2015-12-18 2017-08-31 中外製薬株式会社 抗ミオスタチン抗体、変異Fc領域を含むポリペプチド、および使用方法
JP7053164B2 (ja) 2015-12-18 2022-04-12 中外製薬株式会社 抗ミオスタチン抗体、変異Fc領域を含むポリペプチド、および使用方法

Also Published As

Publication number Publication date
CN115028721A (zh) 2022-09-09
SG11201610812WA (en) 2017-07-28
MX2018007145A (es) 2018-08-15
AU2016372934B2 (en) 2023-10-05
MY189425A (en) 2022-02-10
TW201808992A (zh) 2018-03-16
KR20170085028A (ko) 2017-07-21
KR20180085711A (ko) 2018-07-27
HK1254755A1 (zh) 2019-07-26
KR102501335B1 (ko) 2023-02-17
JP2017148069A (ja) 2017-08-31
TWI749057B (zh) 2021-12-11
RU2018125431A (ru) 2020-01-20
KR20240058997A (ko) 2024-05-03
CN108473562B (zh) 2022-06-17
RU2018125431A3 (ko) 2020-07-06
JP2022097485A (ja) 2022-06-30
TWI605057B (zh) 2017-11-11
BR112018011073A2 (pt) 2018-11-21
AU2016372934A1 (en) 2018-05-10
EP3390443A4 (en) 2019-11-13
KR20230027321A (ko) 2023-02-27
CA3002422A1 (en) 2017-06-22
TW202231662A (zh) 2022-08-16
CA3002422C (en) 2024-04-16
SG10201707267RA (en) 2017-10-30
JP7053164B2 (ja) 2022-04-12
PH12018501280A1 (en) 2019-01-28
TW201726718A (zh) 2017-08-01
KR101820637B1 (ko) 2018-01-19
JP2017112997A (ja) 2017-06-29
WO2017104783A1 (en) 2017-06-22
CN108473562A (zh) 2018-08-31
EP3390443A1 (en) 2018-10-24
AR107078A1 (es) 2018-03-21
EA201891420A1 (ru) 2019-02-28
JP2024023427A (ja) 2024-02-21

Similar Documents

Publication Publication Date Title
JP7049392B2 (ja) 抗ミオスタチン抗体、変異Fc領域を含むポリペプチド、および使用方法
JP7342177B2 (ja) 抗ミオスタチン抗体および使用方法
JP6142069B1 (ja) 抗ミオスタチン抗体、変異Fc領域を含むポリペプチド、および使用方法
EA041641B1 (ru) Антитела к миостатину, полипептиды, содержащие варианты fc-областей, и способы их применения

Legal Events

Date Code Title Description
TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170412

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170508

R150 Certificate of patent or registration of utility model

Ref document number: 6142069

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250